In the Claims:

Claim 1 (currently amended) A composition ~~product~~ comprising an amount of at least one Ccd25 phosphatase inhibitor in combination with at least one other anti-cancer agent ~~for a therapeutic use which is simultaneous, separate or spread over time in~~ sufficient for the treatment of cancer.

Claim 2 (currently amended) ~~Product according to~~ A composition of claim 1, ~~characterized in that~~ wherein the Cdc25 phosphatase inhibitor ~~combined with the other anti-cancer agent~~ is a compound of the ~~general~~ formula ~~(I)~~



(I)

in which:

R^1 ~~represents a~~ is selected from the group consisting of hydrogen, ~~atom or an~~ alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, -(CH_2)-X-Y, -(CH_2)-Z-NR^5R^6 ~~radical or a~~ and –$CHR^{35}R^{36}$ ~~radical~~ in which R^{35} and R^{36} form together with the carbon atom which carries them ~~an~~ indanyl or tetralinyl ~~radical~~, or ~~also~~ R^{35} and R^{36} form together with the carbon atom which carries them a saturated heterocycle ~~containing~~ of 5 to 7 ring members and 1 to 2 heteroatoms ~~chosen from~~ selected from the group consisting of O, N and S, the nitrogen atoms of said heterocycle being optionally

substituted by consisting of O, N and S, the nitrogen atoms of said heterocycle being optionally substituted by ~~radicals chosen from the~~ alkyl ~~radicals and the~~ or benzyl ~~radical~~,

R^1 also being able, when W ~~represents~~ is O, to ~~represent moreover a~~ be carbocyclic aryl ~~radical~~ optionally substituted 1 to 3 times by substituents ~~chosen~~ independently ~~from a~~ selected from the group consisting of halogen, ~~atom and an~~ alkyl, haloalkyl ~~or~~ and alkoxy ~~radical~~,

X ~~representing~~ is a bond or ~~a linear or branched~~ alkylene ~~radical containing~~ of 1 to 5 carbon atoms,

Y ~~representing~~ is a saturated carbon-containing cyclic system ~~containing~~ of 1 to 3 condensed rings ~~chosen~~ selected independently from rings with 3 to 7 ring members, or Y ~~representing a~~ is saturated heterocycle containing 1 to 2 heteroatoms ~~chosen~~ independently ~~from~~ selected from the group consisting of O, N and S and attached to ~~the~~ X ~~radical~~ by an N or CH member, said saturated heterocycle ~~moreover~~ containing 2 to 6 additional members ~~chosen~~ independently selected from the group consisting of ~~from~~ $-CHR^7-$, -CO-, $-NR^8-$, -O- and -S-, R^7 ~~representing a~~ is hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~ and R^8 ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom or an~~ alkyl ~~or~~ and aralkyl ~~radical~~, or ~~also~~ Y ~~representing a~~ is carbocyclic or heterocyclic aryl ~~radical~~ optionally substituted 1 to 3 times by substituents ~~chosen~~ independently ~~from the group constituted by a~~ selected from the group consisting of halogen ~~atom~~, ~~an~~ alkyl ~~radical~~, ~~a~~ halaoalkyl ~~radical~~, ~~an~~ alkoxy ~~radical~~, ~~a~~ haloalkoxy ~~radical~~, ~~a~~ hydroxy ~~radical~~, ~~a~~ nitro ~~radical~~, ~~a~~ cyano ~~radical~~, ~~the~~ phenyl ~~radical~~, ~~an~~ SO_2NHR^9 ~~radical and an~~ and $-NR^{10}R^{11}$ ~~radical~~, R^9 ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom or an~~ alkyl ~~or~~ and phenyl ~~radical~~, and R^{10} and R^{11} are independently ~~representing~~ alkyl ~~radicals~~,

Z ~~representing~~ is a bond or ~~a linear or branched~~ alkylene ~~radical containing~~ of 1 to 5 carbon atoms,

R^5 and R^6 ~~being chosen~~ are independently selected from the group consisting of ~~from a~~ hydrogen ~~atom~~, ~~an~~ alkyl, aralkyl ~~or~~ and $-(CH_2)_n-OH$ ~~radical~~ in which n ~~represents~~ is an integer from 1 to 6,

or R^5 ~~representing an~~ is selected from the group consisting of alkoxycarbonyl, haloalkoxycarbonyl ~~or~~ and aralkoxycarbonyl ~~radical~~ and R^6 ~~representing a~~ is hydrogen ~~atom~~ or ~~a~~ methyl ~~radical~~,

or ~~also~~ R^5 and R^6 ~~forming~~ form together with the nitrogen atom a heterocycle with 4 to 7 ring members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being ~~chosen~~ independently selected from the group consisting of ~~from the~~ $-CR^{12}R^{13}$-, -O-, -S- and $-NR^{14}$- ~~radicals~~, R^{12} and R^{13} are independently ~~representing~~ each time that they occur ~~a~~ hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~, and R^{14} ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom or an~~ alkyl ~~or~~ and aralkyl ~~radical~~, or ~~also~~ R^{14} ~~representing a~~ is phenyl ~~radical~~ optionally substituted 1 to 3 times by substituents ~~chosen~~ independently selected from the group consisting of ~~from a~~ halogen, ~~atom and an~~ alkyl and alkoxy ~~radical~~,

R^2 ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom or an~~ alkyl ~~or~~ and aralkyl ~~radical~~;

or ~~also~~ R^1 and R^2 ~~forming~~ form together with the nitrogen atom a heterocycle with 4 to 8 ring members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being ~~chosen~~ independently selected from the group consisting of ~~from the~~ $-CR^{15}R^{16}$-, -O-, -S- and $-NR^{17}$- ~~radicals~~, R^{15} and R^{16} independently ~~representing~~ are each time that they occur ~~a~~ hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~, and R^{17} ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom~~ or ~~an~~ alkyl ~~or~~ and aralkyl ~~radical~~;

R^3 ~~represents a~~ is selected from the group consisting of hydrogen ~~atom~~, ~~a~~ halogen ~~atom~~, ~~or an~~ alkyl, haloalkyl ~~or~~ and alkylthio ~~radical~~;

R^4 ~~represents an~~ is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, cyano, amino, $-CH_2-COOR^{18}$, $-CH_2-CO-NR^{19}R^{20}$ ~~or~~ and $-CH_2-NR^{21}R^{22}$ ~~radical~~, or R^4 ~~represents~~ ~~a~~ is carbocyclic or heterocyclic aryl ~~radical~~ optionally substituted 1 to 4 times ~~by~~ substituents ~~chosen~~ independently selected from the group consisting of ~~from a~~ halogen, ~~atom and an~~ alkyl,

haloalkyl, alkoxy, haloalkoxy ~~or~~ and –$NR^{37}R^{38}$ ~~radical~~, or ~~also~~ R^4 ~~representing a~~ is phenyl ~~radical~~ possessing two substituents which form together ~~a~~ methylenedioxy or ethylenedioxy ~~radical~~,

R^{18} ~~representing a~~ is hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~,

R^{19} ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom~~, ~~an~~ alkyl ~~radical or an~~ and aralkyl ~~radical~~ the aryl ~~group~~ of which is optionally substituted 1 to 3 times by substituents ~~chosen~~ independently ~~from the group constituted by a~~ selected from the group consisting of halogen ~~atom~~, ~~an~~ alkyl ~~radical~~, ~~a~~ haloalkyl ~~radical~~, ~~an~~ alkoxy ~~radical~~, ~~a~~ haloalkoxy ~~radical~~, ~~a~~ hydroxy ~~radical~~, ~~a~~ nitro ~~radical~~, ~~a~~ cyano ~~radical~~, ~~the~~ phenyl ~~radical~~, ~~an~~ – SO_2NHR^{23} ~~radical~~ and ~~an~~ –$NR^{24}R^{25}$ ~~radical~~, R^{23} ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom or an~~ alkyl ~~or~~ and phenyl ~~radical~~, and R^{24} and R^{25} independently ~~representing~~ are alkyl ~~radicals~~,

R^{20} ~~representing a~~ is hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~,

or ~~also~~ R^{19} and R^{20} ~~forming~~ form together with the nitrogen atom a heterocycle with 4 to 7 ring members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being ~~chosen~~ independently selected from the group consisting of ~~from the~~ -$CR^{26}R^{27}$-, -O-, -S- and -NR^{28}- ~~radicals~~, R^{26} and R^{27} independently ~~representing~~ are each time that they occur ~~a~~ hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~, and R^{28} ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom or an~~ alkyl ~~or~~ and aralkyl ~~radical~~, or ~~also~~ R^{28} ~~representing a~~ is phenyl ~~radical~~ optionally substituted 1 to 3 times by substituents ~~chosen~~ independently selected from the group consisting of ~~from a~~ halogen, ~~atom and an~~ alkyl ~~or~~ and alkoxy ~~radical~~,

R^{21} ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom~~, ~~an~~ alkyl and ~~radical or an~~ aralkyl, ~~radical~~ the aryl ~~group~~ of which is optionally substituted 1 to 3 times by substituents ~~chosen~~ independently ~~from the group constituted by a~~ selected from the group consisting of halogen ~~atom~~, ~~an~~ alkyl ~~radical~~, ~~a~~ haloalkyl ~~radical~~, ~~an~~ alkoxy ~~radical~~, ~~a~~ haloalkoxy ~~radical~~, ~~a~~ hydroxy ~~radical~~, ~~a~~ nitro ~~radical~~, ~~a~~ cyano ~~radical~~, ~~the~~ phenyl ~~radical~~, ~~an~~ –SO_2NHR^{29}

~~radical~~ and ~~an~~ –$NR^{30}R^{31}$ ~~radical~~, R^{29} ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom or an~~ alkyl ~~or~~ and phenyl ~~radical~~, and R^{30} and R^{31} independently ~~representing~~ are alkyl ~~radicals~~,

R^{22} ~~representing a~~ is hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~,

or ~~also~~ R^{21} and R^{22} ~~forming~~ form together with the nitrogen atom a heterocycle with 4 to 7 ring members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being ~~chosen~~ independently selected from the group consisting of ~~from the~~ -$CR^{32}R^{33}$-, -O-, -S- and –NR^{34}- ~~radicals~~, R^{32} and R^{33} independently ~~representing~~ are each time that they occur ~~a~~ hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~, and R^{34} ~~representing a~~ is selected from the group consisting of hydrogen, ~~atom~~, ~~an~~ alkyl ~~or~~ and aralkyl ~~radical~~, or ~~also~~ R^{34} ~~representing a~~ is phenyl ~~radical~~ optionally substituted 1 to 3 times by substituents ~~chosen~~ independently selected from the group consisting of ~~from a~~ halogen, ~~atom and an~~ alkyl ~~or~~ and alkoxy ~~radical~~,

R^{37} and R^{38} being ~~chosen~~ independently from ~~a~~ hydrogen ~~atom~~, ~~atom and an~~ or alkyl ~~radical~~ or R^{37} and R^{38} ~~forming~~ form together with the nitrogen atom a heterocycle with 4 to 7 ring members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle ~~being chosen~~ are independently selected from the group consisting of ~~from the~~ -$CR^{39}R^{40}$-, -O-, -S- and –NR^{41}- ~~radicals~~, R^{39} and R^{40} independently ~~representing~~ are each time that they occur ~~a~~ hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~, and R^{41} ~~representing a~~ is hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~; and

W ~~represents~~ is O or S;

or a pharmaceutically acceptable salt ~~of a compound of general formula (I)~~ thereof.

Claim 3 (currently amended) ~~Product according to~~ A composition of claim 2, ~~characterized in that~~ wherein the compound of ~~general~~ formula (I) ~~or its pharmaceutically acceptable salt is chosen from the following compounds~~ is selected from the group consisting of:

- 5-{[2-(dimethylamino)ethyl]amino}-2-methyl-1,3-benzothiazole-4,7-dione;
- 2-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]-1,3-benzothiazole-4,7-dione;
- 2-methyl-5-[(2-piperidin-1-ylethyl)amino]-1,3-benzothiazole-4,7-dione; and
- 2-(2-chloro-6-fluorophenyl)-5-{[2-(dimethylamino)ethyl]amino}-1,3-benzothiazole-4,7-dione;

and the pharmaceutically acceptable salts ~~of the latter~~ thereof.

Claim 4 (currently amended) ~~Product according to~~ A composition of claim 1, ~~characterized in that~~ wherein the Cdc25 phosphatase inhibitor ~~combined with the other anti-cancer agent~~ is a compound of the ~~general~~ formula ~~(II)~~

(II)

in which:

A ~~represents an (A1) radical~~ has the formula of



(A1)

or



(A2)

in which two of ~~the~~ R^1, R^2, R^3, R^4 and R^5 ~~groups represent~~ are hydrogen ~~atoms~~ and ~~the~~ other three are ~~chosen~~ independently selected from the group consisting of ~~from a~~ hydrogen ~~atom~~, ~~a~~ halogen, ~~atom and an~~ alkyl, hydroxy, alkoxy, alkylcarbonyloxy, alkylthio ~~or~~ and $-NR^6R^7$ ~~radical~~, it being understood ~~moreover~~ that:

- either R^1 and one of R^2 and R^4 are ~~chosen~~ independently ~~from a~~ hydroxy, alkylcarbonyloxy ~~or~~ and $-NR^6R^7$ ~~radical~~,
- or R^2 and one of R^3 and R^5 are ~~chosen~~ independently ~~from a~~ hydroxy, alkylcarbonyloxy ~~or~~ and $-NR^6R^7$ ~~radical~~,
- or R^4 and one of R^3 and R^5 are ~~chosen~~ independently ~~from a~~ hydroxy, alkylcarbonyloxy ~~or~~ and $-NR^6R^7$ ~~radical~~,
- or ~~also~~ one of R^1, R^3 and R^5 is ~~chosen from a~~ hydroxy, alkylcarbonyloxy and $-NR^6R^7$ ~~radical~~, and the remainder B-N(W)-X-Y is attached to ~~the~~ A ~~radical~~ by a nitrogen atom, R^6 and R^7 ~~forming~~ form together with the nitrogen atom a heterocycle with 4 to 7 ring members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being ~~chosen~~ independently selected from the group consisting of ~~from the~~ $-CR^8R^9-$, -O-, -S- and $-NR^{10}-$ ~~radicals~~, R^8 and R^9 independently ~~representing~~ are each time that they occur ~~a~~ hydrogen, ~~atom or an~~ alkyl, alkoxy, benzyloxycarbonylamino ~~or~~ and dialkylamino ~~radical~~, and R^{10} independently ~~representing~~ is each time that it occurs ~~a~~ hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~;

~~or also A represents an (A2) radical~~

~~in which~~:

- either R^{11} and one of R^{13}, R^{14} and R^{15} ~~represent~~ are hydroxy ~~radicals~~ while the other ~~radicals from~~ R^{13}, R^{14} and R^{15} ~~as well as~~ and R^{16} ~~represent~~ are hydrogen ~~atoms~~,
- or R^{12} and R^{16} ~~represent~~ are hydroxy ~~radicals~~ while R^{11}, R^{13}, R^{14} and R^{15} ~~represent~~ are hydrogen ~~atoms~~,

B ~~represents a~~ is selected from the group consisting of -CO-, -NH-CO-$(CH_2)_n$- ~~or~~ and -$(CH_2)_p$- ~~radical~~, n ~~being~~ is an integer from 0 to 3 and p ~~being~~ is an integer from 0 to 1;

W ~~represents a~~ is hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~;

X ~~represents a~~ is selected from the group consisting of -$(CH_2)_q$-, -$(CH_2)_q$-NH ~~or~~ and -CO-$(CH_2)_r$- ~~radical~~, q ~~being~~ is an integer from 1 to 6 and r is an integer from 0 to 6;

or ~~also the~~ B-N(W)-X-Y ~~group~~ is such that it represents ~~the radical~~



in which B is as defined above, t is an integer from 0 to 2, s is an integer from 0 to 1 and R^{17} and R^{18} ~~represent radicals chosen~~ are independently ~~from a~~ hydrogen ~~atom and an~~ or alkyl ~~radical~~; and:

- when X ~~represents a~~ is -$(CH_2)_q$- or –CO-$(CH_2)_r$- ~~radical~~, then Y ~~represents a radical~~ is



in which R^{19} ~~represents a~~ is selected from the group consisting of hydrogen ~~atom~~, ~~a~~ nitro, alkyl, alkylthio, $NR^{21}R^{22}$, $-SO_2-NR^{23}R^{24}$, $-NH-SO_2-R^{25}$ ~~or~~ and $-O-P(O)(OR^{26})(OR^{27})$ ~~radical~~,

R^{21} and R^{22} independently ~~representing a~~ are hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~, or

R^{23} and R^{24} ~~representing~~ are together with the nitrogen atom which carries them a heterocycle with 5 to 7 ring members, the complimentary members of which are ~~chosen~~ independently selected from the group consisting of ~~from the~~ $-CHR^{28}-$, $-NR^{29}-$, -O- and –S-, $-R^{28}-$ and $-R^{29}-$ ~~representing~~ are, independently each time that they occur, a hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~,

R^{25} ~~representing an~~ is selected from the group consisting of alkyl, haloalkyl, ~~radical or one of the~~ aryl, heteroaryl, aralkyl or heteroalkyl, ~~radicals~~ the aryl or heteroaryl nucleus of which is optionally substituted by at least one ~~or more radicals chosen independently from a~~ member selected from the group consisting of halogen, ~~atom and~~ alkyl, haloalkyl, hydroxy, alkoxy ~~or~~ and nitro ~~radicals~~, except for the optional nitrogen atoms of the heteroaryl nucleus, the optional substituents of which are ~~chosen from~~ alkyl ~~radicals~~, R^{26} and R^{27} ~~being chosen~~ are independently ~~from~~ alkyl ~~radicals~~,

and R^{20} ~~represents a~~ is selected from the group consisting of hydrogen, ~~atom or an~~ alkyl, alkoxy ~~or~~ and alkylthio ~~radical~~,

or ~~also~~ Y ~~represents the (T) radical represented below~~ is



(T)

in which R^{20} ~~represents a~~ is selected from the group consisting of hydrogen, ~~atom or an~~ alkyl, alkoxy ~~or~~ and alkylthio ~~radical~~,

- when X ~~represents a~~ is $-(CH_2)_q-NH-$ ~~radical~~ or when ~~the~~ B-N(W)-X-Y ~~group is such that it represents the radical~~ is



then Y ~~represents~~ is exclusively ~~an~~ $-SO_2-R^{30}$ ~~radical~~ in which R^{30} ~~represents an~~ is selected from the group consisting of alkyl, haloalkyl, ~~radical or one of the~~ aryl, heteroaryl, aralkyl ~~or~~ and heteroaryl nucleus of which is optionally substituted by at least one or ~~more radicals chosen independently from a~~ member selected from the group consisting of halogen, ~~atom and~~ alkyl, haloalkyl, hydroxy, alkoxy ~~or~~ and nitro ~~radicals~~, except for the optional nitrogen atoms of the heteroaryl nucleus the optional substituents of which are ~~chosen from~~ alkyl ~~radicals~~;

it being understood ~~moreover~~ that when ~~the~~ B-N(W)-X-Y ~~group is such that it represents the radical~~



then B ~~represents~~ is exclusively ~~a~~ -CO- or $-(CH_2)-$ ~~radical~~;

or a pharmaceutically acceptable salt ~~of such a compound~~ thereof.

Claim 5 (currently amended) ~~Product according to~~ A composition of claim 1, ~~characterized in that~~ wherein the Cdc25 phosphatase inhibitor ~~combined with the other anti-cancer agent~~ is ~~chosen from~~ menadione and its analogues.

Claim 6 (currently amended) ~~Product according to one~~ A composition of ~~claims~~ claim 1 ~~to 5, characterized in that~~ wherein the anti-cancer agent ~~combined with the Cdc25 phosphatase inhibitor~~ is ~~chosen~~ selected from the group consisting of analogues of DNA bases, type I and/or II ~~topoisomerass~~ topoisomerase inhibitors, compounds interacting with the cell spindle, compounds acting on the cytoskeleton, inhibitors of the transduction of the signal passing through the heterotrimeric G proteins, prenyltransferase inhibitors, cyclin-dependent kinase (CDKs) inhibitors, alkylating agents and inhibitors of DNA synthesis and cell division.

Claim 7 (currently amended) ~~Product according to~~ A composition of claim 6, ~~characterized in that~~ wherein the anti-cancer agent ~~combined with the Cdc25 phosphatase inhibitor~~ is a type I and/or II topoisomerase inhibitor.

Claim 8 (currently amended) ~~Product according to~~ A composition of claim 7, ~~characterized in that~~ wherein the type I and/or II topoisomerase inhibitor is camptothecin or one of its analogues.

Claim 9 (currently amended) ~~Product according to~~ A composition of claim 8, ~~characterized in that~~ wherein the type I and/or II topoisomerase inhibitor is a compound of the ~~general~~ formula ~~(III)~~



(III)

in racemic, enantiomeric form or all combinations ~~of these forms~~ thereof, in which

R_1 ~~represents a~~ is selected from the group consisting of lower alkyl, ~~a~~ lower alkynyl, ~~a~~ lower haloalkyl, ~~a~~ lower alkoxy lower alkyl ~~or a~~ and lower alkylthio lower alkyl;

R_2, R_3 and R_4 ~~represent~~ are, independently selected from the group consisting of i) H, halo, lower halo alkyl, lower alkyl, lower alkenyl, cyano, lower cyano alkyl, nitro, lower nitro alkyl, amido, lower amido alkyl, hydrazino, lower hydrazino alkyl, azido, lower azido alkyl, -$(CH_2)_mNH_6R_7$, -$(CH_2)_mOR_6$, -$(CH_2)_m$-SR_6, -$(CH_2)_mCO_6R_6$, -$(CH_2)_mNR_6C(O)R_8$, -$(CH_2)_mC(O)R_8$, -$(CH_2)_mOC(O)R_8$, -$O(CH_2)_mNR_6R_7$, -$OC(O)NR_6R_7$, -$OC(O)(CH_2)_mCO_2R_6$, or ii) $(CH_2)_n$[N=X], OC(O)[N=X], $(CH_2)_mOC(O)$[N=X] ~~the following radicals~~ optionally substituted (~~i.e. substituted~~ one to four times on the aryl ~~group~~ or ~~the~~ heterocycle) ~~or not substituted, in which~~ [N=X], ~~in this invention, represents~~ is a heterocyclic ~~group~~ with 4 to 7 ring members with the nitrogen atom N, which is a member of the heterocyclic group, and X ~~represents~~ is the remaining members, necessary to complete the heterocyclic group, selected from the group ~~constituted by~~ consisting of O, S, CH_2, CH, N, NR_9 and COR_{10}~~)~~, aryl or lower aryl alkyl, in which the optional substituents are ~~chosen~~ from the group ~~constituted by a~~ consisting of lower alkyl, halo, nitro, amino, lower alkylamino, lower haloalkyl, lower hydroxy alkyl, lower alkoxy and lower alkoxy lower alkyl; or R_2 and R_3 together form a chain ~~with~~ of 3 or 4 mombers, in which the elements of the chain are selected from the group ~~constituted by~~ consisting of CH, CH_2, O, S, N ~~or~~ and NR_9;

R_5 ~~represents~~ is selected from the group consisting of i) H, halo, lower halo alkyl, lower alkyl, lower alkoxy, lower alkoxy lower alkyl, lower alkylthio lower alkyl, cycloalkyl, lower cycloalkyl alkyl, cyano, cyano alkyl, lower alkyl lower sulphonyl alkyl, lower hydroxy alkyl, nitro, $(CH_2)_mC(O)R_8$, $(CH_2)_mNR_6C(O)R_8$, $(CH_2)_mNR_6R_7$, $(CH_2)_mN(CH_3)(CH_2)_nNR_6R_7$, $(CH_2)_mOC(O)R_8$, $(CH_2)_mOC(O)NR_6R_7$, $(CH_2)_mS(O)qR_{11}$,

$(CH_2)_mP(O)R_{12}R_{13}$ and $(CH_2)_2P(S)R_{12}R_{13}$, or ii) $(CH_2)_n[N=X]$, $OC(O)[N=X]$, $(CH_2)_mOC(O)[N=X]$ ~~one of the following radicals~~ optionally substituted (i.e. one to four times on the aryl or heteroaryl group) ~~or not substituted~~: alkyl, in which the optional substituents ~~are chosen from the group constituted by a~~ selected from the group consisting of lower alkyl, halo, nitro, amino, lower alkyl amino, lower halo alkyl, lower hydroxy alkyl, lower alkoxy and lower alkoxy lower alkyl;

R_6 and R_7 ~~represent~~ are, independently selected from the group consisting of i) H, ~~a~~ lower alkyl, lower hydroxy alkyl, lower alkyl lower amino alkyl, lower amino alkyl, cycloalkyl, lower cycloalkyl alkyl, lower alkenyl, lower alkoxy lower alkyl, lower halo alkyl, or ii) ~~one of the following radicals~~ aryl or lower aryl alkyl optionally substituted (~~i.e.~~ one to four times on the aryl ~~group~~) ~~or not substituted~~: ~~in which the optional substituents are chosen from the group constituted by a~~ selected from the group consisting of lower alkyl, halo, nitro, amino, lower alkyl amino, lower halo alkyl, lower hydroxy alkyl, lower alkoxy, and lower alkoxy lower alkyl;

R_8 ~~represents~~ is selected from the group consisting of i) H, ~~a~~ lower alkyl, lower hydroxy alkyl, amino, lower alkyl amino, lower alkyl amino lower alkyl, lower amino alkyl, cycloalkyl, lower cycloalkyl alkyl, lower alkenyl, lower alkoxy, lower alkoxy lower alkyl and lower halo alkyl, or ii) ~~one of the following radicals~~ aryl or lower aryl alkyl optionally substituted (~~i.e.~~ one to four times on the aryl ~~group) or not substituted: aryl or lower aryl alkyl, in which the optional substituents are chosen from the group constituted by a~~ selected from the group consisting of lower alkyl, halo, nitro, amino, lower alkyl amino, lower halo alkyl, lower hydroxy alkyl, lower alkoxy, ~~or~~ and lower alkoxy lower alkyl;

R_9 ~~represents~~ is selected from the group consisting of H, ~~a~~ lower alkyl, lower halo alkyl, aryl, ~~or~~ and aryl substituted by at least one ~~or more groups chosen from the~~ lower alkyl

~~radical~~, halo, nitro, amino, lower alkyl amino, lower halo alkyl, lower hydroxy alkyl, lower alkoxy, ~~or~~ and lower alkoxy lower alkyl;

R_{10} ~~represents~~ is selected from the group consisting of H, ~~a~~ lower alkyl, lower halo alkyl, amino, lower alkoxy, aryl ~~or~~ and aryl optionally substituted (~~i.e., presenting~~ by one to four substituents on the aryl ~~group) by one or more groups chosen from the~~ lower alkyl ~~radical~~, lower halo alkyl, lower hydroxy alkyl, ~~or~~ and lower alkoxy lower alkyl;

CH, CH_2, O, S, N ~~or~~ and NR_9;

R_{11} ~~represents a~~ is selected from the group consisting of lower alkyl, aryl, $-(CH_2)_mOR_{14}$, $-(CH_2)_mSR_{14}$, $-(CH_2)_2NR_{14}R_{15}$, ~~or~~ and $-(CH_2)_m[N=X]$;

R_{12} and R_{13} ~~representing~~ are, independently selected from the group consisting of ~~a~~ lower alkyl, aryl, lower alkoxy, aryloxy ~~or~~ and amino;

R_{14} and R_{15} ~~representing~~ are, independently selected from the group consisting of H, ~~a~~ lower alkyl, ~~or~~ and aryl;

R_{18} and R_{19} ~~representing~~ are, independently selected from the group consisting of H, halo, lower alkyl, lower alkoxy ~~or~~ and hydroxy;

R_{20} ~~represents~~ is H or halo;

m is ~~a whole number comprised between~~ an integer from 0 and 6;

n is 1 or 2; and

q ~~represents a whole number~~ is an integer from 0 to 2; and [N=X] ~~repreents~~ is a heterocyclic group with 4 to 7 members, X representing the chain necessary to complete said heterocyclic group and selected from the group ~~constituted by~~ consisting of O, S, CH_2, CH, N, NR_9 and COR_{10};

or a pharmaceutically acceptable salt ~~of the latter~~ thereof.

Claim 10 (currently amended) ~~Product according to~~ A composition of claim 9,

~~characterized in that~~ wherein the compound of ~~general~~ formula (III) or its pharmaceutically acceptable salt is ~~chosen from~~ selected from the group consisting of diflomotecan and (+)-9-chloro-5-ethyl-5-hydroxy-10-methyl-12-(4-methylpiperidinomethyl)-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-c]quinoline-3,15-dione and its pharmaceutically acceptable salts.

Claim 11 (currently amended) ~~Product according to~~ A composition of claim 6, ~~characterized in that~~ wherein the anti-cancer agent ~~combined with the Cdc25 phosphatase inhibitor~~ is an inhibitor of the transduction of the signal passing through the heterotrimeric G proteins.

Claim 12 (currently amended) ~~Product according to~~ A composition of claim 11, ~~characterized in that~~ wherein the inhibitor of the transduction of the signal passing through the heterotrimeric G proteins is ~~chosen from the compounds~~ compound of the general formula ~~(IV)~~



(IV)

corresponding to the sub-formulae ~~(IV_A) or (IV_B)~~:



(IV_A)



(IV_B)

in which:

X ~~represents~~ is R_{12} and Y ~~represents~~ is R_8, or X and Y complete a ring with 6 members, ~~the~~ X-Y ~~group representing the~~ is -$CH(R_8)$-$CH(R_9)$- ~~radical~~;

R_1 ~~represents~~ is selected from the group consisting of H, ~~an~~ alkyl, alkylthio ~~or~~ and cycloalkylthio ~~radical~~;

R_2 and R_3 independently ~~represent~~ are selected from the group consisting of H, ~~or an~~ alkyl ~~or~~ and cycloalkyl ~~radical~~;

R_4 ~~represents~~ is H_2 or O;

R_5 ~~represents~~ is selected from the group consisting of H, ~~or one of the~~ alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl or heterocyclyalkyl ~~radicals~~, ~~these radicals~~ aryl being optionally substituted by ~~radicals chosen from the group comprising an~~ a member selected from the group consisting of alkyl, -O-R_{10}, -$S(O)_mR_{10}$ (m ~~representing~~ is 0, 1, or 2), -$N(R_{10})(R_{11})$, -N-C(O)-R_{10}, NH-(SO_2)-R_{10}, -CO_2-R_{10}, -C(O)-$N(R_{10})(R_{11})$, and -(SO_2)-$N(R_{10})(R_{11})$ ~~radical~~;

R_6 and R_7 independently ~~represent~~ are selected from the group consisting of H, ~~a~~ -C(O)-NH-CHR_{13}-CO_2R_{14}, ~~radical~~, ~~or one of the~~ alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl ~~or~~ and heterocyclylalkyl ~~radicals~~, ~~these radicals~~ aryls being optionally substituted by ~~radicals chosen from the group comprising the~~ a member selected from the group consisting of OH, alkyl, ~~or~~ alkoxy, -$N(R_{10})(R_{11})$, -COOH, -$CON(R_{10})(R_{11})$, and halo ~~radicals~~,

or R_6 and R_7 together form ~~an~~ aryl ~~radical~~ or ~~a~~ heterocycle;

R_8 and R_9 independently ~~represent~~ are selected from the group consisting of H, ~~or one of the~~ alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl ~~or~~ and heterocyclylalkyl ~~radicals~~, ~~these radicals~~ being optionally substituted by ~~radicals chosen~~

~~from the group comprising the~~ a member selected from the group consisting of OH, alkyl, ~~or~~ alkoxy, -N(R_{10})(R_{11}), -COOH, -CON(R_{10})(R_{11}), and halo ~~radicals~~,

or R_8 and R_9 together form ~~an~~ aryl ~~radical~~ or ~~a~~ heterocycle;

R_{10} and R_{11} independently ~~represent~~ are selected from the group consisting of H, ~~an aryl radical or heterocyelyl, or an~~ alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl ~~or~~ and heterocyclylalkyl ~~radical~~;

R_{12} ~~represents~~ is selected from the group consisting of NR_9, S, or O;

R_{13} ~~represents an~~ is alkyl ~~radical~~ optionally substituted by a ~~radical chosen from the~~ member selected from the group consisting of alkyl, -O-R_{10}, -$S(O)_mR_{10}$ (m ~~representing~~ is 0, 1, or 2), and -N(R_{10})(R_{11}) ~~radicals~~;

R_4 ~~represents~~ is H_2 ~~or~~ and alkyl ~~radicals~~;

and the pharmaceutically acceptable salts ~~of the latter~~ thereof.

Claim 13 (currently amended) ~~Product according to~~ A composition of claim 12, ~~characterized in that~~ wherein the compound of ~~general~~ formula (IV) ~~or its pharmaceutically acceptable salt is chosen from~~ is selected from the group consisting of 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8 tetrahydroimidazo[1,2a]pyrazine and its dimer form, bis-1,1' -{7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine}~~disulphide~~ disulfide ~~or~~ and (1*R*)-1-[({(2*R*)-2-amino-3-[(8*S*)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-*a*]pyrazine-7-(8*H*)-yl]-3-oxopropyl}dithio)methyl]-2-[(8*S*)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-*a*]pyrazine-7(8*H*)-yl]-2-oxoethylamine, and the pharmaceutically acceptable salts ~~of these compounds~~ thereof.

Claim 14 (currently amended) ~~Product according to~~ A composition of claim 6,

~~characterized in that~~ wherein the anti-cancer agent ~~combined with the Cde25 phophatases inhibitor~~ is a prenyltransferase inhibitor.

Claim 15 (currently amended) ~~Product according to~~ A composition of claim 14, ~~characterized in that~~ wherein the farnesyltransferase inhibitor is ~~chosen from the group comprised~~:

- of a compound of the ~~general~~ formula ~~(V)~~



(V)

in which:

n1 ~~represents~~ is 0 or 1;

X ~~represents~~ is, independently each time that it occurs, $-(CHR^{11})_{n3}(CH_2)_{n4}Z(CH_2)_{n5}$;

Z ~~representing~~ is selected from the group consisting of O, $N(R^{12})$, S, ~~or~~ and a bond;

n^3 ~~representing~~ is, independently each time that they ~~occurs~~ occur, 0, 1, 2, or 3;

Y ~~represents~~ is, independently each time that it occurs, selected from the group consisting of CO, CH_2, CS, ~~or~~ and a bond;

R^1 ~~represents one of the radicals~~ is



~~or~~ and –N($R^{24}R^{25}$);

each of R^2, R^{11}, and R^{12} ~~representing~~ is, independently each time that it occurs, selected from the group consisting of H, ~~or an~~ optionally substituted ~~radical chosen from the group consisting of a~~ (C_{1-6})alkyl ~~radical~~ and ~~an~~ aryl ~~radical~~, ~~said optionally substituted radical being~~ optionally substituted by at least one ~~radical chosen from the~~ member of R^8 and R^{30} ~~radicals~~, each substituent being chosen independently of the others;

R^3 ~~represents~~ is, independently each time that it occurs, selected from the group consisting of H, ~~or an~~ optionally substituted ~~radical chosen from the group consisting of the~~ (C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{2-6})alkynyl, (C_{3-6})cycloalkyl, (C_{3-6})cycloalkyl(C_{1-6})alkyl, (C_{5-7})cycloalkenyl, (C_{5-7})cycloalkenyl(C_{1-6})alkyl, aryl, aryl(C_{1-6})alkyl, heterocyclyl, and heterocyclyl(C_{1-6})alkyl ~~radicals~~, said optionally ~~substituted~~ substituents being ~~optionally substituted by~~ at least one ~~radical chosen from the~~ R^{30} ~~radicals~~, each substituent being chosen independently of the others;

each of R^4 and R^5 ~~represents~~, is independently each time that it occurs, selected from the group consisting of H, ~~or an~~ optionally substituted ~~radical chosen from the group consisting of the~~ (C_{1-6})alkyl, (C_{3-6})cycloalkyl, aryl and heterocyclyl ~~radicals~~, said optionally ~~substituted~~ substituent

~~radical~~ being ~~optionally substituted by~~ at least one ~~radical chosen from the~~ R^{30} ~~radicals~~, each substituent being chosen independently of the others, or R^4 and R^5 taken together with the carbon atoms to which they are attached together form ~~an~~ aryl ~~radical~~;

R^6 ~~represents~~ is, independently each time that it occurs, selected from the group consisting of H, ~~or~~ an optionally substituted ~~radical chosen from the group consisting of the~~ (C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{2-6})alkynyl, (C_{3-6})cycloalkyl, (C_{3-6})cycloalkyl(C_{1-6})alkyl, (C_{5-7})cycloalkenyl, (C_{5-7})cycloalkenyl(C_{1-6})alkyl, aryl, aryl(C_{1-6})alkyl, heterocyclyl, and heterocyclyl(C_{1-6})alkyl ~~radicals~~, said optionally ~~substituted~~ substituent being ~~optionally substituted by~~ at least one ~~radical chosen from the~~ OH, (C_{1-6})alkyl, (C_{1-6})alkoxy, -N(R^8R^9), -COOH, -CON(R^8R^9) and halo ~~radicals~~, each substituent being chosen independently of the others;

R^7 ~~represents~~ is, independently each time that it occurs, selected from the group consisting of H, =O, =S, H, ~~or~~ and an optionally substituted ~~radical chosen~~ from the group consisting of ~~the~~ (C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{3-6})cycloalkyl, (C_{3-6})cycloalkyl(C_{1-6})alkyl, (C_{5-7})cycloalkenyl, (C_{5-7})cycloalkenyl(C_{1-6})alkyl, aryl, aryl(C_{1-6})alkyl, heterocyclyl, and heterocyclyl(C_{1-6})alkyl ~~radicals~~, said optionally ~~substituted~~ substituent ~~radical~~ being ~~optionally substituted by~~ at least one member selected from the group consisting of ~~radical chosen from the~~ OH, (C_{1-6})alkyl, (C_{1-6})alkoxy, -N(R^8R^9), -COOH, -CON(R^8R^9) and halo ~~radicals~~, each substituent being chosen independently of the others;

each of R^8 and R^9 ~~representing~~, is independently each time that it occurs, selected from the group consisting of H, (C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{2-6})alkynyl, aryl, ~~or~~ and aryl(C_{1-6})alkyl,

R^{10} ~~represents~~ is C;

or, when n1=0, R^6 and R^7 can be taken together with the carbon atoms to which they are attached to form ~~an~~ aryl ~~radical~~ or cyclohexyl;

R^{21} ~~represents~~ is, independently each time that it occurs, selected from the group consisting of H ~~or~~ and an optionally substituted ~~radical chosen from the group consisting of the~~ (C_{1-6})alkyl and aryl(C_{1-6})alkyl ~~radicals~~, said optionally ~~substituted~~ substituent ~~radical~~ being ~~optionally substituted by at least one radical chosen~~ selected from ~~the~~ R^8 and R^{30} ~~radicals~~, each substituent being chosen independently of the others;

R^{22} ~~represents~~ is selected from the group consisting of H, (C_{1-6})alkylthio, (C_{3-6})cycloalkylthio, R^8–CO-, ~~or a substituent of formula~~ and



;

each of R^{24} and R^{25} ~~represents~~ is, independently each time that it occurs, selected from the group consisting of H, (C_{1-6})alkyl ~~or~~ and aryl(C_{1-6})alkyl;

R^{30} ~~represents~~ is, independently each time that it occurs, selected from the group consisting of (C_{1-6})alkyl, -O-R^8, -S(O)$_{n6}R^8$, -S(O)$_{n7}$N(R^8R^9), -N(R^8R^9), -CN, -NO_2, -CO_2R^8, -CON(R^8R^9), -NCO-R^8, ~~or~~ and halogen, each of n6 and n7 ~~representing~~ being, independently each time that it occurs, 0, 1 or 2;

said heterocyclyl ~~radical~~ being selected from the group consisting of azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl ~~sulphone~~ sulfone, furyl, imidazolidinyl, imidazolidinyl, imidazolinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothizolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl-N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl, thiamorpholinyl, thiamorpholinyl ~~sulphoxide~~ sulfoxide, thiazolyl, thiazolinyl, thienothienyl ~~or~~ and thienyl;

said ~~radical~~ aryl being phenyl or naphthyl;

it being understood that:

when n1=1, R^{10} is C and R^6 ~~represents~~ is H, then R^{10} and R^7 can form, taken together, ~~the radical~~



;

or when n1=1, R^{10} is C and R^7 is =O, -H, or =S, then R^{10} and R^6 can form, taken together, ~~the radical~~



,

with each of X^1, X^2 and X^3 ~~representing~~ being, independently, selected from the group consisting of H, ~~a~~ halogen ~~atom~~, $-NO_2$, $-NCO-R^8$, CO_2R^8, -CN, ~~or~~ and $-CON(R^8R^9)$; and

when R^1 is $-N(R^{24}R^{25})$, then n3 ~~represents~~ is 1, each of n4 and n5 ~~represents~~ is 0, Z is a bond, and R^3 and R^{11} can form, taken together, ~~the radical~~



with n2 ~~representing~~ being an integer from 1 to 6, and each of X^4 and X^5 ~~representing~~ is, independently, selected from the group consisting of H, (C_{1-6})alkyl ~~or~~ and aryl, or X^4 and X^5 ~~forming~~ form, taken together, ~~a~~ (C_{3-6})cycloalkyl ~~radical~~;

~~of~~ or a compound of the ~~general~~ formula ~~(IV)~~



(VI)

in which:

R^1 ~~represents~~ is selected from the group consisting of H, ~~or an~~ alkyl, $-O-R^{10}$, $-SR^{10}$, ~~or~~ and $NR^{11}R^{12}$ ~~radical~~;

R^2 ~~represents~~ is H or ~~an~~ alkyl ~~radical~~;

R^3, R^4 and R^5 ~~represent~~ are, independently, selected from the group consisting of H, ~~a~~ halogen, ~~atom or an~~ alkyl, trihalomethyl, hydroxy, cyano ~~or~~ and alkoxy ~~radical~~;

R^6 ~~represents~~ is H or ~~an~~ alkyl ~~radical~~;

R^7 ~~represents~~ is selected from the group consisting of H, ~~a~~ halogen, ~~atom or an~~ alkyl, hydroxyalkyl, amino and hydroxycarbonyl ~~radical~~;

R^8 and R^9 ~~represent~~ are, independently, selected from the group consisting of H, ~~a~~ halogen, ~~atom or a~~ cyano, alkyl, trihalomethyl, alkoxy, alkylthio ~~or~~ and dialkylamino ~~radical~~;

R^{10} ~~represents~~ is selected from the group consisting of H, ~~or an~~ alkyl ~~or~~ and alkylcarbonyl ~~radical~~;

R^{11} ~~represents~~ is H or ~~an~~ alkyl ~~radical~~;

R^{12} ~~represents~~ is selected from the group consisting of H, ~~or an~~ alkyl ~~or~~ and alkylcarbonyl ~~radical~~;

and Y ~~represents~~ is O or S;

- and a pharmaceutically acceptable salt ~~of a compound of general formula (V) or of a compound of general formula (VI)~~ thereof.

Claim 17 (currently amended) ~~Product according to~~ A composition of claim 16, ~~characterized in that~~ wherein the farnesyltransferase inhibitor is 1-(2-(1-((4-cyano)phenylmethyl)imidazol-4-yl)-1-oxoethyl-2,5-dihydro-4-(2-methoxyphenyl)imidazo[1,2c][1,4]benzodiazepine~~,~~ or 4-(2-bromophenyl)-1,2-dihydro-8-fluoroimidazol[1,2a][1,4]-benzodiazepine or ~~one of its~~ a pharmaceutically acceptable ~~salts~~ salt thereof.

Claim 18 (currently amended) ~~Product according to~~ A composition of claim 6, ~~characterized in that~~ wherein the anti-cancer agent ~~combined with the Cdc25 phosphatase inhibitor~~ is a cyclin-dependent kinase (CDK) inhibitor.

Claim 19 (currently amended) ~~Product according to~~ A composition of claim 18, ~~characterized in that~~ wherein the CDK inhibitor ~~is chosen from the compounds of general formula (VII)~~ has the formula



(VII)

in racemic, enantiomeric form or all combination of these forms, in which

A ~~represents a~~ is selected from the group consisting of hydrogen, ~~atom, a~~ halogen ~~atom~~, ~~a~~ formyl, cyano, nitro, guanidinoaminomethylenyl, (1,3-dihydro-2-oxoindol)-3-ylidenemethyl, alkylcarbonyl, aralkylcarbonyl, ~~or~~ heteroaralkylcarbonyl and ~~radical, or also a~~ –L-NR^1R^2 ~~radical~~ in which L ~~represents an~~ is alkelene ~~radical~~ and R^1 and R^2 are ~~chosen~~ independently ~~from a~~ hydrogen ~~atom and an~~ or alkyl ~~radical~~ or R^1 and R^2 taken together with the nitrogen atom which carries them form a heterocycle with 5 to 7 ring members, the complimentary members being ~~chosen~~ independently ~~from the group comprising~~ selected from the group consisting of -CH_2-, -NR^3-, -S- and -O-, R^3, independently ~~representing~~ is each time that it occurs ~~a~~ hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~;

X ~~represents a~~ is selected from the group consisting of hydrogen ~~atom, an~~ alkylthio, aralkylthio, ~~or~~ aralkylthio ~~radical~~, and ~~or also an~~ NR^4R^5 ~~radical~~ in which R^4 ~~represents an~~ is selected from the group consisting of alkyl ~~radical~~, ~~a~~ hydroxyalkyl ~~radical~~, ~~a~~ cycloalkyl ~~radical~~ optionally substituted by at least one ~~or more radicals chosen from the~~ alkyl, hydroxy, ~~and~~ amino ~~radicals~~, an aralkyl, ~~radical~~ the aryl ~~radical~~ of which is optionally substituted by at least one member selected from the group consisting of ~~or more radicals chosen from a~~ halogen ~~atom~~, ~~the~~ cyano ~~radical~~, ~~the~~ nitro ~~radical~~, ~~and the~~ alkyl ~~or~~ and alkoxy ~~radicals~~, or ~~also~~ R^4 ~~represents a~~ is heteroaryl or heteroarylalkyl ~~radical~~, the heteroaryl ~~radical of the heteroaryl or heteroarylalkyl radicals~~ being optionally substituted by at least one ~~or more~~ alkyl ~~radicals~~ and R^5 ~~represents a~~ is hydrogen ~~atom~~, or R^4 and R^5 taken together with the nitrogen atom which carries them form a heterocycle with 5 to 7 ring members, the complimentary members being ~~chosen~~ independently selected from the group consisting of ~~from the group comprising~~ $-CH_2-$, $-NR^6-$, -S- and -O-, R^6, independently ~~representing~~ is each time that it occurs ~~a~~ hydrogen ~~atom~~ or ~~an~~ alkyl or hydroxyalkyl ~~radical~~;

Y ~~represents~~ is NH or ~~an~~ oxygen ~~atom~~;

Z ~~represents~~ is selected from the group consisting of a bond, ~~or an~~ alkyl ~~or~~ and alkylthioalkyl ~~radical~~; and

Ar ~~represents a~~ is carbocyclic aryl ~~radical~~ optionally substituted 1 to 3 times by a member selected from the group consisting of ~~radicals chosen independently from a~~ halogen ~~atom~~, ~~the~~ cyano ~~radical~~, ~~the~~ nitro ~~radical~~, ~~an~~ alkyl, ~~or~~ alkoxy ~~radical~~ and ~~an~~ $-NR^7R^8$ ~~radical~~ in which R^7 and R^8 independently ~~represent a~~ hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~ or R^7 and R^8 taken together with the nitrogen atom which carries them form a heterocycle with 5 to 7 ring members, the complimentary members being ~~chosen~~ independently selected from the group consisting of ~~from~~

~~the group comprising~~ -CH_2-, -NR^9-, -S- and -O-, R^9 independently ~~representing~~ is each time that it occurs ~~a~~ hydrogen ~~atom~~ or ~~an~~ alkyl ~~radical~~;

or ~~also~~ Ar ~~represents a~~ is heterocyclic aryl ~~radical~~ having 5 or 6 members and whose heteroatom or heteroatoms are ~~chosen from~~ selected from the group consisting of nitrogen, oxygen or ~~sulphur~~ sulfur ~~atoms~~, said heteroatoms being optionally oxidized ~~(Ar can represent for example the oxidopyridyl radical)~~ and said heterocyclic aryl ~~radical~~ being able to be optionally substituted by at least one ~~or more radicals chosen independently from the~~ member selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl and dialkylamnioalkyl ~~radicals~~;

and the pharmaceutically acceptable salts ~~of these compounds~~ thereof.

Claim 20 (currently amended) ~~Product according to~~ A composition of claim 18, ~~characterized in that~~ wherein the CDK inhibitor is ~~chosen from~~ roscovitine ~~or~~ and analogues.

Claim 21 (currently amended) A compound ~~characterized in that it is~~ of (1*R*)-1-[({(2*R*)-2-amino-3-[(8*S*)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo [1,2-*a*]pyrazine-7(8*H*)-yl]-3-oxopropyl}dithio)methyl]-2-[(8*S*)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-*a*]pyrazine-7(8*H*)-yl]-2-oxoethylamine, or a pharmaceutically acceptable salt thereof.

Claim 22 (currently amended) A pharmaceutically acceptable salt ~~according to~~ of claim 21, ~~characterized in that it~~ which is (1*R*)-1-[({(2*R*)-2-amino-3-[(8*S*)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-*a*]pyrazin-7(8*H*)-yl]-3-oxopropyl}dithio)methyl]-2-[(8*S*)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-*a*]pyrazin-7(8*H*)-yl]-2-oxoethylamine tetrahydrochloride.

Claim 23 (currently amended) A preparation process for ~~making~~ preparing the salt of claim 22, ~~said process being characterized in that it comprises the following steps~~ comprising:

1) reacting approximately 2 equivalents of (8*S*)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyrazine with approximately one equivalent of Boc-Cys-Cys-Boc in a polar aprotic solvent; and
2) reacting in a lower alcohol the ~~disulphide~~ disulfide derivative obtained ~~after~~ in stage 1) with an excess of hydrochloric acid in solution in a lower alcohol.

Please add the following claims:

Claim 24 (new) A method of treating cancer in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof an amount of at least one Cdc25 phosphatase inhibitor and at least one other anti-cancer agent which administration is simutaneously, separately or spread over time.

Claim 25 (new) The method of claim 24 wherein the administration is simultaneously.

Claim 26 (new) The method of claim 24 wherein the administration is at the same time by different routes.

Claim 27 (new) The method of claim 24 wherein the administration of the product is sequentially.